What To Know: Under the agreement signed June 22, OrthoCellix, holder of Ocugen's NeoCart regenerative medicine assets, will merge with a Carisma subsidiary, becoming a wholly owned subsidiary of Carisma.
Read Also: Trump Media Shares Move Higher After Board Approves $400 Million Buyback
The merged company's board will include five directors from OrthoCellix and one from Carisma. Pre-merger Carisma shareholders will also receive contingent value rights tied to future proceeds from legacy assets and partnerships, including Carisma's agreement with Moderna.
The deal includes standard closing conditions and investor protections, such as lock-up agreements and support agreements from key stakeholders.
The companies aim to complete the merger following shareholder approvals, Nasdaq listing compliance, and SEC registration effectiveness. A $5 million investment from Ocugen is expected to support the merger's close.
According to data from Benzinga Pro, Ocugen has a 52-week high of $1.98 and a 52-week low of 52 cents. The stock was down 8.29%, trading at approximately 97 cents at the time of publication.
Read Also: Hims & Hers Health Stock Is Tumbling Monday: What’s Happening?
How To Buy OCGN Stock
By now you're likely curious about how to participate in the market for Ocugen – be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of possible trading platforms here. Many will allow you to buy “fractional shares,” which allows you to own portions of stock without buying an entire share.
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
